Drug Trial Radar · NCT07417917
QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
102
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Jun 1, 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II clinical study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of QLS12010 capsules in the treatment of moderate to severe Hidradenitis Suppurativa (HS). The study is comprised of two parts: Part A is a multi-center, open-label, single-dose group proof-of-concept study; Part B is a randomized, double-blind, placebo-controlled dose-ranging study. The overall duration of this study is up to 32 weeks, inclusive of the Screening Period, Treatment Period of up to 24 weeks, and the 4-Week Follow-Up Period for safety assessment.
Conditions
- Adults With Moderate-to-severe Hidradenitis Suppurativa
Interventions
QLS12010Drug
QLS12010 oral capsules
PlaceboDrug
Matching placebo oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change form Baseline in a total abscess and inflammatory nodule(AN) count [Part B]Time frame: Week 16
- Incidence and severity of treatment emergent Adverse Events [Part A]Time frame: up to approximately 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.